HIGHLIGHTS
- who: Barzell zone and colleagues from the Council Clinical Trials Unit (MRC CTU) at UCL and sponsored by University College Cancer Research UK have published the research: Regional histopathology and prostate MRI positivity: a secondary analysis of the PROMIS trial, in the Journal: (JOURNAL)
- what: The fact that the study was blinded (i.e. MRI interpretation and combined TPM-TRUS biopsy were independent) and that such a rigorous reference standard was applied in previously biopsy-nau00efve men gives PROMIS its unique advantage, which is its relative freedom from spectrum, selection and sampling biases. The aim . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.